

DERM DIX

A 29-year-old black man whose history included gallstones and a recurrent left leg ulcer presented with acute chest pain, fever, dyspnea, and a new and painful ulcer on his left leg. He was not a smoker and didn't drink alcohol. What's your diagnosis?

TORONTO — A complete blood count showed an increased number of activated endothelial cells, said Dr. Hakeem Sam of McGill University, Montreal.

The leg ulcer was associated with sickle cell disease. The interaction between the activated endothelial and sickle cells led to increased expression of endothelial cell adhesion molecules, which promoted thrombotic vaso-occlusion, causing the ulcer.

Leg ulcers are not uncommon complications of sickle cell disease, especially in Jamaica and Nigeria. Data from a study in the *British Journal of Haematology* showed that 75% of 183 sickle cell patients in Jamaica had significantly more venous incompetence, compared with 39% of controls (*Br. J. Haematol.* 2002; 119:567-71).

Reported treatments for leg ulcers in sickle cell disease patients include wet dressings, hydroxyurea, transfusions, recombinant erythropoietin, zinc sulfate supplements, and surgical grafts and flaps.

In this case, the wound base was cleaned via autolytic and enzymatic debridement to avoid trauma to the wound bed. The wound was treated with a nonadherent dressing, and the patient received medication for local and systemic pain. Foam, Hydrofiber, and calcium alginate were used to manage wound exudate, according to Dr. Sam.

—Heidi Splete

New Drug Slows Cell Destruction In Sickle Cell

SAN DIEGO — A new drug helps slow accelerated red blood cell destruction that is a characteristic feature of sickle cell disease, Kenneth I. Ataga, M.D., reported at a press briefing during the annual meeting of the American Society of Hematology.

The drug, known as ICA-17043, is part of new class of drugs known as Gardos channel inhibitors. Potassium loss from red blood cells (RBCs) may occur via the Gardos channel, explained Dr. Ataga of the University of North Carolina, Chapel Hill. ICA-17043 blocks this channel and prevents accelerated potassium efflux, which in turn prevents dehydration of RBCs.

In a 12-week, multicenter, phase II study, he and his associates randomized 80 patients with sickle cell anemia to one of three groups: low dose ICA-17043 (6 mg/day), high dose ICA17043 (10 mg/day), or placebo. Total hemoglobin increased significantly from baseline among patients in the high-dose group and markers of RBC destruction decreased, compared with those in the placebo group.

—Doug Brunk



COURTESY DR. HAKEEM SAM

VERBATIM

'The fact is, when elderly people are depressed, they don't take their ACE inhibitors.


It's as simple as that.'

Dr. William J. Hall, p. 51

Exercise testing with nuclear imaging is a reliable diagnostic tool for your patients at cardiac risk.¹

Too bad some of them may find it difficult

to keep up.



Adenoscan provided interpretable imaging results in 98.7% of patients.² Diagnosis. Prognosis.³ How you use the test is up to you. So for your patients unable to exercise adequately, use pharmacologic stress with Adenoscan.

Intravenous Adenoscan® (adenosine injection) is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately.

Fatal cardiac arrest, sustained ventricular tachycardia (requiring resuscitation), and nonfatal myocardial infarction have been reported coincident with Adenoscan infusion. Patients with unstable angina may be at greater risk.

Side effects that were seen most often included flushing (44%), chest discomfort (40%), and dyspnea (28%). Side effects usually resolve quickly when infusion is terminated and generally do not interfere with test results.

Please see brief summary of prescribing information on adjacent page.

Patent protected to 2015.

1. Wackers FJ. In: Dilsizian V, et al, eds. *Atlas of Nuclear Cardiology*. Philadelphia, Pa: Current Medicine Inc; 2003:76-77.
2. Cerqueira MD, et al. *J Am Coll Cardiol.* 1994;23:384-389.
3. Klocke FJ, et al. *Circulation.* 2003;108:1404-1418.

ADENOSCAN®
adenosine injection

www.adenoscan.com 1-800-888-7704 ©2005 Astellas Pharma US, Inc. AS1562 2/05

 **astellas**
Astellas Pharma US, Inc.